Information Provided By:
Fly News Breaks for June 22, 2018
ABMD
Jun 22, 2018 | 05:00 EDT
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $480 after hosting an institutional investor meeting at the company's headquarters. It was another positive meeting as clinicians continue to realize the value of Impella in treating a sick patient population, O'Brien tells investors in a research note. Further, the analyst now believes that Impella Connect should make monitoring patients for the hospital staff much easier in the future. He believes management continues to develop new technologies that should keep Abiomed "well ahead of any future competition." O'Brien does not see a "med tech story that is nearly as compelling as this one." The analyst keeps an Overweight rating on the shares.
News For ABMD From the Last 2 Days
There are no results for your query ABMD